Literature DB >> 2916561

Coexistence of myelodysplastic syndrome and untreated chronic lymphocytic leukemia with development of acute myeloid leukemia immediately after treatment of chronic lymphocytic leukemia.

A W Bracey1, A M Maddox, L Immken, S M Hsu, M E Marks.   

Abstract

A 72-year-old man originally seen for anemia and thrombocytopenia was determined to have chronic lymphocytic leukemia (CLL). Bone marrow examination at the time of CLL diagnosis revealed a small but significant population of atypical blasts. Cytogenetic analysis of the bone marrow aspirate disclosed chromosomal abnormalities (-7, +8) suggestive of a myelodysplastic syndrome. Shortly after treatment of the CLL, there was proliferation of the previously noted blast population, which cytochemical studies demonstrated to be of the myeloid series thus indicating acute myeloid leukemia superimposed on CLL. This report presents microscopic, cytogenetic, immunophenotypic, and cytochemical evidence to document the evolution of acute myeloid leukemia in the bone marrow of a patient with CLL after one course of chemotherapy.

Entities:  

Mesh:

Year:  1989        PMID: 2916561     DOI: 10.1002/ajh.2830300310

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

1.  Treatment-related acute myeloid leukemia in a chronic lymphocytic leukemia patient: role of fludarabine?

Authors:  Smith Giri; Vijaya Raj Bhatt; Sumesh Khanal; Apar Kishor Ganti
Journal:  Ther Adv Hematol       Date:  2015-04

2.  A case of CLL that was successfully treated resulted in the immediate development of AML from a coexistent myeloid line that had been suppressed.

Authors:  Mohammad Ansari; Michael Auerbach; Huzefa Bahrain
Journal:  Clin Case Rep       Date:  2014-12-22

3.  Multi Cytogenetic Changes in a Patient as Co-Existing MDS and CLL Progresses.

Authors:  Xiangxin Li; Jiale Ma; Luqun Wang; Shuxin Yan; Fanglin Li; Lingling Wang; Lin Wang; Guosheng Li; Daoxin Ma; Hao Li
Journal:  Onco Targets Ther       Date:  2021-01-08       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.